Drug Manufacturer Interest In Rx-To-OTC Pipeline Growing – FDA’s Ganley
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeing increased activity from drug companies wanting to switch their prescription drug products over-the-counter, according to Center for Drug Evaluation & Research OTC Drug Products Division Director Charles Ganley, MD
You may also be interested in...
Test Market/Actual Use Study Combination Proposed For Switch Candidates
Consumer purchasing and use of potential Rx-to-OTC switch drugs may be most accurately predicted by a combination of actual use studies with a form of test marketing, according to Bristol-Myers Squibb Executive Medical Director Carola Friedman, MD
Test Market/Actual Use Study Combination Proposed For Switch Candidates
Consumer purchasing and use of potential Rx-to-OTC switch drugs may be most accurately predicted by a combination of actual use studies with a form of test marketing, according to Bristol-Myers Squibb Executive Medical Director Carola Friedman, MD
Test Market/Actual Use Study Combination Proposed For Switch Candidates
Consumer purchasing and use of potential Rx-to-OTC switch drugs may be most accurately predicted by a combination of actual use studies with a form of test marketing, according to Bristol-Myers Squibb Executive Medical Director Carola Friedman, MD